Sign inJoin waitlistJoin the waitlist

John Heymach

EMP Co-Leader · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present
Thoracic/Head and Neck Medical Oncology Department · University of Texas M D Anderson Cancer Center
Present
Department of Thoracic/Head and Neck Medical Oncology · University of Texas M D Anderson Cancer Center
Present

Dana-Farber Cancer Institute
2000–2003
Internal Medicine
Brigham and Women's Hospital
1998–1999
Stanford University
Stanford University School of Medicine
1994–1998

Research

Lung cancer
Review · New England Journal of Medicine · 2008 · 2,141 citations
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Cancer Discovery · 2018 · 1,415 citations
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase…
Journal of Clinical Oncology · 2019 · Last of 21 authors · 1,075 citations

Jianjun Zhang
172 papers · 2 as a fellow
Don Gibbons
142 papers
Lauren Byers
114 papers · 7 as a fellow
Stephen Swisher
98 papers
Tina Cascone
91 papers · 17 as a fellow
Xiuning Le
91 papers
JL
Joanna Lee
79 papers · 17 as a resident
Ara Vaporciyan
77 papers
BS
Boris Sepesi
67 papers
Mehmet Altan
56 papers · 1 as a fellow
John Minna
55 papers
Natalie Vokes
53 papers · 1 as a fellow

Grants

Deciphering the Structural Determinants of Response and Resistance to HER2-Targeted Antibody-Drug Conjugates and Tyrosine Kinase Inhibitors for HER2-Mutant Non-Small Cell Lung Cancer
National Cancer Institute · R01
Contact PI · $1.4M · University of Tx Md Anderson Can Ctr
2025–2030
Targeting Lung Cancer Vulnerabilities
National Cancer Institute · P50
PI · $10.9M · Ut Southwestern Medical Center
1997–2026
The University of Texas MD Anderson Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $146.9K · University of Tx Md Anderson Can Ctr
1996–2026
Molecular and Immunological Heterogeneity of Small Cell Lung Cancer (SCLC) and Its Impact on Relapse and Therapeutic Response
National Cancer Institute · U01
PI · $3M · University of Tx Md Anderson Can Ctr
2021–2026

Clinical trials

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 3
AstraZeneca
2018–2028
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 3
M.D. Anderson Cancer Center
2017–2027
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
Principal investigator · Active not recruiting · Phase 2
AstraZeneca
2017–2026
Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2016